Since January 2015
- Analyze new investment opportunities in the field of anticancer therapies (oncolytic viruses, vaccines, immunotherapy, metabolic approaches, etc) - Map biomedical anti-cancer therapies and technologies (by attending (inter)-national congresses & meetings, networking, using biomedical knowledge databases, going through relevant publications & clinical trials, going through granted/provisional patent applications etc) - Manage evaluation / content / knowledge database - Work-related ICT manager
June 2013 --- December 2014
More specifically my work at PX Biosolutions entagled managing and driving preclinical experiments concerning PoC, safety-toxicity and immunogenicity and other IND enabling studies for a cancer vaccine (DCtag) against ovarian cancer. Concurrently, I assessed and reviewed new anti-cancer therapies that might be of interest to DROIA (biotech private investor) for further funding and/or involvement.
August 2008 --- June 2013
My research focuses on establishing reference values on several immunological attributes in cats. Focus lies on regulatory cell types such as NK cells and Tregs. These reference values are then compared to values obtained in cats infected with feline coronaviruses (FECV and FIPV) to obtain more knowledge on the impact of these viruses on the feline immune system.
July 2007 --- August 2007
Doctor of Philosophy (PhD) in Veterinary Microbiology and Immunobiology from Universiteit Gent in 2013
Bioscience engineer in Biosciences from Universiteit Gent in 2008
moderne talen wiskunde in ASO from Broederschool Sint-Niklaas in 2002